Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PTGX Protagonist Therapeutics

Pre-Mkt 12-16 06:05:54 EST

94.79

-0.56

-0.59%

盘前94.41

-0.38-0.40%

06:00 EST

High96.54	Low94.17	Vol959.98K
Open95.41	D1 Closing95.35	Amplitude2.49%
Mkt Cap5.93B	Tradable Cap4.09B	Total Shares62.52M
T/O91.20M	T/O Rate2.22%	Tradable Shares43.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PTGX","market":"US","secType":"STK","nameCN":"Protagonist Therapeutics","latestPrice":94.79,"timestamp":1765832400000,"preClose":95.35,"halted":0,"volume":959977,"hourTrading":{"tag":"盘前","latestPrice":94.41,"preClose":94.79,"latestTime":"06:00 EST","volume":204,"amount":19337.09064,"timestamp":1765882818646},"delay":0,"floatShares":43154809,"shares":62515666,"eps":0.720214,"marketStatus":"Pre-Mkt","change":-0.56,"latestTime":"12-16 06:05:54 EST","open":95.41,"high":96.54,"low":94.17,"amount":91203709.25878,"amplitude":0.024856,"askPrice":151.66,"askSize":200,"bidPrice":94.01,"bidSize":123,"shortable":3,"etf":0,"ttmEps":0.720214,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1470888000000,"exchange":"NASDAQ","adjPreClose":94.79,"preHourTrading":{"tag":"盘前","latestPrice":94.41,"preClose":94.79,"latestTime":"06:00 EST","volume":204,"amount":19337.09064,"timestamp":1765882818646},"postHourTrading":{"tag":"盘后","latestPrice":94.79,"preClose":94.79,"latestTime":"19:30 EST","volume":21089,"amount":1999220.9,"timestamp":1765845032821},"volumeRatio":0.7628294697395361,"impliedVol":0.4397,"impliedVolPercentile":0.2129},"requestUrl":"/m/hq/s/PTGX","defaultTab":"news","newsList":[{"id":"2591766292","title":"Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide","url":"https://stock-news.laohu8.com/highlight/detail?id=2591766292","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591766292?lang=en_us&edition=fundamental","pubTime":"2025-12-15 04:13","pubTimestamp":1765743183,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) shares are back on traders radar after the company and partner Takeda highlighted 52 week Phase 3 VERIFY data for rusfertide in polycythemia vera ahead of an ASH oral presentation.\nSee our latest analysis for Protagonist Therapeutics.\nThe VERIFY update lands on top of a powerful run, with the share price now at $95.35 after a 63.33% 3 month share price return and a huge 3 year total shareholder return of 882.99%. This suggests momentum and expectations are...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/valuing-protagonist-therapeutics-ptgx-after-new-52-week-phas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/valuing-protagonist-therapeutics-ptgx-after-new-52-week-phas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PTGX","BK4139","DCF"],"gpt_icon":0},{"id":"2590363346","title":"Protagonist Therapeutics Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2590363346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590363346?lang=en_us&edition=fundamental","pubTime":"2025-12-09 03:53","pubTimestamp":1765223580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 14:53 ET (19:53 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"gpt_icon":0},{"id":"2589333230","title":"Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera","url":"https://stock-news.laohu8.com/highlight/detail?id=2589333230","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589333230?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:19","pubTimestamp":1765192760,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics, Inc. announced new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera. The results were presented in an oral presentation at the 67th American Society of Hematology Annual Meeting and Exposition on December 6, 2025. The study demonstrated that rusfertide provided sustained hematocrit control and response, defined by the absence of phlebotomy eligibility, with no new safety signals observed. Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the U.S. Food & Drug Administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL1HWfBh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"gpt_icon":0},{"id":"2589600826","title":"Takeda Reports 52-Week Phase 3 Data Showing Rusfertide Maintains Hematocrit Control in Polycythemia Vera","url":"https://stock-news.laohu8.com/highlight/detail?id=2589600826","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589600826?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031431,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics, Inc. announced that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera  will be presented in an oral presentation at the 67th American Society of Hematology  Annual Meeting and Exposition. The data indicate that 61.9% of patients continuously treated with rusfertide maintained absence of phlebotomy eligibility from baseline to Week 52, demonstrating durable hematocrit control. Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the U.S. Food & Drug Administration . The companies plan to advance rusfertide towards regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL992GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"gpt_icon":0},{"id":"2585107011","title":"J.P. Morgan Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585107011","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585107011?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:18","pubTimestamp":1763727508,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Brian Cheng maintained a Buy rating on Protagonist Therapeutics yesterday and set a price target of $93.00. The company’s share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-protagonist-therapeutics-ptgx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-protagonist-therapeutics-ptgx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"gpt_icon":0},{"id":"2584189379","title":"U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe's","url":"https://stock-news.laohu8.com/highlight/detail?id=2584189379","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584189379?lang=en_us&edition=fundamental","pubTime":"2025-11-20 16:25","pubTimestamp":1763627108,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe'sNov 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agios P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nL4N3WW0LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPK","ACM","LU0170899867.USD","KGC","SG9999015952.SGD","MDGL","IE0002141913.USD","ENTG","UNH","3NVD.UK","NVDX","DY","JACK","LU1868837136.USD","NVD2.UK","SEMR","LU1548497426.USD","NVDA","SNVD.UK","ROP","LOW","NVDL","Q","NVD","PANW","TGT","VVV","NVDS","LU1868836591.USD","TJX","GLOB","AGIO","NVDU","AVAV","LU2756315664.SGD","PTGX","AIZ","WSM","IONQ","BHVN","RVMD","NVD3.UK","NVDY","RRC","2NVD.UK","NVIW.SI","NVDD","LU1169589451.USD","NVDS.UK","LU2279689827.SGD"],"gpt_icon":0},{"id":"2584905939","title":"Top Executive Sells Thousands in Protagonist Therapeutics Stock!","url":"https://stock-news.laohu8.com/highlight/detail?id=2584905939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584905939?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:12","pubTimestamp":1763604742,"startTime":"0","endTime":"0","summary":"New insider activity at Protagonist Therapeutics ( ($PTGX) ) has taken place on November 19, 2025. CMO Arturo MD Molina recently sold 2,712 shares ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executive-sells-thousands-in-protagonist-therapeutics-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executive-sells-thousands-in-protagonist-therapeutics-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTGX"],"gpt_icon":0},{"id":"2584308929","title":"Protagonist Therapeutics Q3 EPS USD -0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2584308929","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584308929?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:58","pubTimestamp":1763571484,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Protagonist Therapeutics Q3 net income USD -39.339 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:05:47.997 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD973YTW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"gpt_icon":0},{"id":"2583680086","title":"H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680086?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:38","pubTimestamp":1763163506,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Protagonist Therapeutics today and set a price target of $80.00. Tsao covers the He...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-protagonist-therapeutics-ptgx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-protagonist-therapeutics-ptgx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"gpt_icon":0},{"id":"2582966385","title":"Protagonist Therapeutics Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2582966385","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582966385?lang=en_us&edition=fundamental","pubTime":"2025-11-11 06:06","pubTimestamp":1762812360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 17:06 ET (22:06 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"gpt_icon":0},{"id":"1184397139","title":"Stock Track | Protagonist Therapeutics Soars 5.11% Following Analyst Price Target Hikes","url":"https://stock-news.laohu8.com/highlight/detail?id=1184397139","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184397139?lang=en_us&edition=fundamental","pubTime":"2025-11-11 03:11","pubTimestamp":1762801874,"startTime":"0","endTime":"0","summary":"Shares of Protagonist Therapeutics (PTGX) are soaring 5.11% in Monday's intraday trading session, buoyed by positive analyst actions from major Wall Street firms. The biotechnology company's stock is...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PTGX"],"gpt_icon":0},{"id":"1181560470","title":"Stock Track | Protagonist Therapeutics Soars 5.11% Following Analyst Price Target Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=1181560470","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181560470?lang=en_us&edition=fundamental","pubTime":"2025-11-11 03:11","pubTimestamp":1762801873,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) stock is experiencing a significant surge in the market, soaring 5.11% during Monday's intraday trading session. This impressive rally comes on the heels of two major...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PTGX"],"gpt_icon":0},{"id":"2582879913","title":"Protagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879913","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879913?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:51","pubTimestamp":1762779102,"startTime":"0","endTime":"0","summary":"Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $65 from $47 and keeps a Neutral rating on the shares. Protagoni...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-65-from-47-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-65-from-47-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"gpt_icon":0},{"id":"2581836768","title":"Protagonist Therapeutics Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2581836768","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581836768?lang=en_us&edition=fundamental","pubTime":"2025-11-08 04:18","pubTimestamp":1762546680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 15:18 ET (20:18 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"gpt_icon":0},{"id":"2581893598","title":"Protagonist Therapeutics Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581893598","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581893598?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:23","pubTimestamp":1762525380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 09:23 ET (14:23 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"gpt_icon":0},{"id":"2581900291","title":"H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581900291","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581900291?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:56","pubTimestamp":1762516560,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Protagonist Therapeutics, with a price target of $80.00. A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-protagonist-therapeutics-ptgx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-protagonist-therapeutics-ptgx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"gpt_icon":0},{"id":"2581006198","title":"Protagonist Therapeutics price target raised to $91 from $74 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2581006198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581006198?lang=en_us&edition=fundamental","pubTime":"2025-11-07 18:30","pubTimestamp":1762511419,"startTime":"0","endTime":"0","summary":"Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $91 from $74 and keeps a Buy rating on the shares. The firm updat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-91-from-74-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-91-from-74-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"gpt_icon":0},{"id":"2581020508","title":"Protagonist Therapeutics Advances Pipeline Amid Financial Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2581020508","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581020508?lang=en_us&edition=fundamental","pubTime":"2025-11-07 13:28","pubTimestamp":1762493335,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics Inc ( ($PTGX) ) has released its Q3 earnings. Here is a breakdown of the information Protagonist Therapeutics Inc presente...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/protagonist-therapeutics-advances-pipeline-amid-financial-loss?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/protagonist-therapeutics-advances-pipeline-amid-financial-loss?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTGX"],"gpt_icon":0},{"id":"2581419028","title":"The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Upcoming Rusfertide Phase 3 Data Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2581419028","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581419028?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:32","pubTimestamp":1762475537,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics has announced that new clinical data on rusfertide in polycythemia vera, including results from the Phase 3 VERIFY study, will be presented at the 67th Annual ASH Meeting in December 2025.\nThese presentations are expected to provide key insights into the durability, safety, and long-term effects of rusfertide treatment, which may be pivotal for future clinical and regulatory decisions.\nWe'll explore how the forthcoming clinical evidence on rusfertide's durability and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/the-bull-case-for-protagonist-therapeutics-ptgx-could-change","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/the-bull-case-for-protagonist-therapeutics-ptgx-could-change","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","PTGX"],"gpt_icon":0},{"id":"2581704542","title":"Protagonist Therapeutics Q3 net loss widens to $39.3 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581704542","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581704542?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:53","pubTimestamp":1762466017,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics Q3 net loss widens to $39.3 mlnOverviewProtagonist Therapeutics reports Q3 net loss of $39.3 mln, increased R&D expenses notedCash reserves of $678.8 mln expected to sustain o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protagonist-inc.com","stockEarnings":[{"period":"1week","weight":0.0503},{"period":"1month","weight":0.1203},{"period":"3month","weight":0.6179},{"period":"6month","weight":0.758},{"period":"1year","weight":1.3074},{"period":"ytd","weight":1.4557}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.041464},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.008489},{"month":3,"riseRate":0.444444,"avgChangeRate":0.070491},{"month":4,"riseRate":0.222222,"avgChangeRate":-0.125222},{"month":5,"riseRate":0.666667,"avgChangeRate":0.20629},{"month":6,"riseRate":0.777778,"avgChangeRate":0.09374},{"month":7,"riseRate":0.555556,"avgChangeRate":0.002773},{"month":8,"riseRate":0.777778,"avgChangeRate":0.16209},{"month":9,"riseRate":0.5,"avgChangeRate":0.00523},{"month":10,"riseRate":0.4,"avgChangeRate":0.039581},{"month":11,"riseRate":0.6,"avgChangeRate":0.076941},{"month":12,"riseRate":0.6,"avgChangeRate":0.022322}],"exchange":"NASDAQ","name":"Protagonist Therapeutics","nameEN":"Protagonist Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protagonist Therapeutics,PTGX,Protagonist Therapeutics股票,Protagonist Therapeutics股票老虎,Protagonist Therapeutics股票老虎国际,Protagonist Therapeutics行情,Protagonist Therapeutics股票行情,Protagonist Therapeutics股价,Protagonist Therapeutics股市,Protagonist Therapeutics股票价格,Protagonist Therapeutics股票交易,Protagonist Therapeutics股票购买,Protagonist Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction